Clinical trial
Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low…
NCT00359164 · University of British Columbia, Other · Completed
Key facts
| NCT number | NCT00359164 |
|---|---|
| Title | Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab. |
| Official title | A Randomized, Controlled, Double-Masked, Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab (Avastin), in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMD) |
| Lead sponsor | University of British Columbia, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Drug |
| Interventions | Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab, Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab, Verteporfin Photodynamic Therapy (SHAM) and bevacizumab |
| Enrollment | 36 |
| Start date | Jul 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Aug 1, 2006 |
| Last update posted | Aug 14, 2008 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: